Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Rigshospitalet, Denmark.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00400504
First received: November 16, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted

November 16, 2006
November 16, 2006
November 2006
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)
Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)

Patients with malignancies are at high risk of developing a thromboembolic complication and their treatment with chemo- and or radiation therapy further enhances this risk.

Conventional haemostatic tests are not suitable as a screening tool of a hypercoagulable state. A hypercoagulable profile identified with the whole blood Thrombelastograph (TEG) Analyzer parameter maximal amplitude (MA) is reported to correlate with thrombotic events in patients undergoing major non-cardial surgery and recurrent ischemic events in patients undergoing percutaneous coronary intervention.

In this study we investigate the correlation between TEG measurements and thromboembolic events in patients with newly diagnosed malignancies.

The hypotheses of this study are:

  1. Patients with malignancies and hypercoagulability, defined as a TEG MA>69 mm and /or R<4 min is at increased risk of developing thromboembolic complications as compared to those with a MA<69 mm and/or a R>4 min.
  2. Hypercoagulability and hence TEG R and MA values are affected by the treatment instituted in these patients (chemo and radiation therapy) rendering the patients more hypercoagulable and hence at increased risk of developing thrombotic complications.
Not Provided
Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
Not Provided
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of cancer

Exclusion Criteria:

  • Mamma cancer
Both
18 Years and older
No
Contact: Louise Bochsen, MSc +4535452033 louise.bochsen@rh.hosp.dk
Denmark
 
NCT00400504
TEG-Onkologi
Not Provided
Not Provided
Rigshospitalet, Denmark
Not Provided
Study Chair: Pär I Johansson, MD Rigshospitalet, Denmark
Study Director: Gedske Daugaard, MD Rigshospitalet, Denmark
Rigshospitalet, Denmark
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP